ARCA biopharma, Inc. (ABIO)
Company Description
ARCA biopharma, Inc., a clinical development stage biopharmaceutical company, engages in the development and commercialization of genetically targeted therapies for cardiovascular diseases.
Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure.
It is also developing Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19.
ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial.
The company was founded in 2004 and is headquartered in Westminster, Colorado.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Dr. Michael R. Bristow M.D., Ph.D. |
Contact Details
Address: 10170 Church Ranch Way, Suite 100 Westminster, Colorado 80021 United States | |
| Phone | (720) 940-2200 |
| Website | arcabio.com |
Stock Details
| Ticker Symbol | ABIO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000907654 |
| CUSIP Number | 00211Y506 |
| ISIN Number | US00211Y5069 |
| Employer ID | 36-3855489 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Dr. Michael R. Bristow M.D., Ph.D. | Co-Founder, President, Chief Executive Officer and Director |
| Thomas A. Keuer | Chief Operating Officer |
| Christopher D. Ozeroff | Senior Vice President, General Counsel and Secretary |
| C. Jeffrey Dekker CPA | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 19, 2023 | ARS | Filing |
| Dec 19, 2023 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Dec 19, 2023 | DEF 14A | Other definitive proxy statements |
| Dec 5, 2023 | 8-K | Current Report |
| Dec 4, 2023 | 8-K | Current Report |
| Oct 18, 2023 | 8-K | Current Report |
| Oct 18, 2023 | 10-Q | Quarterly Report |
| Sep 11, 2023 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Jul 21, 2023 | 8-K | Current Report |
| Jul 21, 2023 | 10-Q | Quarterly Report |